These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 30197261)

  • 21. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.
    Wu YL; Cheng Y; Zhou J; Lu S; Zhang Y; Zhao J; Kim DW; Soo RA; Kim SW; Pan H; Chen YM; Chian CF; Liu X; Tan DSW; Bruns R; Straub J; Johne A; Scheele J; Park K; Yang JC;
    Lancet Respir Med; 2020 Nov; 8(11):1132-1143. PubMed ID: 32479794
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer.
    Nygaard AD; Garm Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
    Lung Cancer; 2013 Mar; 79(3):312-7. PubMed ID: 23238036
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib.
    D'Angelo SP; Janjigian YY; Ahye N; Riely GJ; Chaft JE; Sima CS; Shen R; Zheng J; Dycoco J; Kris MG; Zakowski MF; Ladanyi M; Rusch V; Azzoli CG
    J Thorac Oncol; 2012 Dec; 7(12):1815-1822. PubMed ID: 23154553
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†.
    Blumenschein GR; Smit EF; Planchard D; Kim DW; Cadranel J; De Pas T; Dunphy F; Udud K; Ahn MJ; Hanna NH; Kim JH; Mazieres J; Kim SW; Baas P; Rappold E; Redhu S; Puski A; Wu FS; Jänne PA
    Ann Oncol; 2015 May; 26(5):894-901. PubMed ID: 25722381
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC.
    Mok TSK; Lopes G; Cho BC; Kowalski DM; Kasahara K; Wu YL; de Castro G; Turna HZ; Cristescu R; Aurora-Garg D; Loboda A; Lunceford J; Kobie J; Ayers M; Pietanza MC; Piperdi B; Herbst RS
    Ann Oncol; 2023 Apr; 34(4):377-388. PubMed ID: 36709038
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219.
    Melosky B; Bradbury P; Tu D; Florescu M; Reiman A; Nicholas G; Basappa N; Rothenstein J; Goffin JR; Laurie SA; Wheatley-Price P; Leighl N; Goss G; Reaume MN; Butts C; Murray N; Card C; Ko J; Blais N; Gray S; Lui H; Brown-Walker P; Kaurah P; Prentice LM; Seymour L
    Lung Cancer; 2019 Jul; 133():48-55. PubMed ID: 31200828
    [TBL] [Abstract][Full Text] [Related]  

  • 27. KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: A meta-analysis of 41 studies.
    Pan W; Yang Y; Zhu H; Zhang Y; Zhou R; Sun X
    Oncotarget; 2016 Feb; 7(7):8373-88. PubMed ID: 26840022
    [TBL] [Abstract][Full Text] [Related]  

  • 28. LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value.
    Facchinetti F; Bluthgen MV; Tergemina-Clain G; Faivre L; Pignon JP; Planchard D; Remon J; Soria JC; Lacroix L; Besse B
    Lung Cancer; 2017 Oct; 112():62-68. PubMed ID: 29191602
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors.
    Kartolo A; Feilotter H; Hopman W; Fung AS; Robinson A
    Cancer Treat Res Commun; 2021; 27():100330. PubMed ID: 33581492
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer.
    Gerber DE; Socinski MA; Neal JW; Wakelee HA; Shirai K; Sequist LV; Rosovsky RP; Lilenbaum RC; Bastos BR; Huang C; Johnson ML; Hesketh PJ; Subramaniam DS; Dietrich MF; Chai F; Wang Y; Kazakin J; Schwartz B; Schiller JH; Brahmer JR; Kelly RJ
    Lung Cancer; 2018 Mar; 117():44-49. PubMed ID: 29496255
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non-Small-Cell Lung Cancer With a Detectable KRAS Mutation Whose Disease Has Progressed After Platinum-Based Chemotherapy.
    Goldman JW; Shi P; Reck M; Paz-Ares L; Koustenis A; Hurt KC
    Clin Lung Cancer; 2016 Jan; 17(1):80-4. PubMed ID: 26432508
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
    Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
    J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas.
    Yu HA; Sima CS; Hellmann MD; Naidoo J; Busby N; Rodriguez K; Riely GJ; Kris MG
    Cancer; 2015 Jun; 121(12):2078-82. PubMed ID: 25781862
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Relevance of EGFR- or KRAS-mutated Subclones in Patients With Advanced Non-small-cell Lung Cancer Receiving Erlotinib in a French Prospective Cohort (IFCT ERMETIC2 Cohort - Part 2).
    Beau-Faller M; Texier M; Blons H; Richard N; Escande F; Melaabi S; Lizard S; De Fraipont F; Longchampt E; Morin F; Zalcman G; Pignon JP; Cadranel J
    Clin Lung Cancer; 2019 May; 20(3):222-230. PubMed ID: 30679079
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plunging Into the PACIFIC: Outcomes of Patients With Unresectable KRAS-Mutated Non-Small Cell Lung Cancer Following Definitive Chemoradiation and Durvalumab Consolidation.
    Barsouk A; Friedes C; Iocolano M; Doucette A; Cohen RB; Robinson KW; D'Avella CA; Marmarelis ME; Kosteva JA; Singh AP; Ciunci CA; Levin WP; Cengel KA; Bradley JD; Feigenberg SJ; Sun L; Aggarwal C; Langer CJ; Yegya-Raman N
    Clin Lung Cancer; 2024 May; 25(3):e161-e171. PubMed ID: 38195320
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The efficacy of first-line chemotherapy is associated with KRAS mutation status in patients with advanced non-small cell lung cancer: a meta-analysis.
    Zhang Y; Fang W; Yan Y; Wang M; Kang S; Sheng J; Zhan J; Chen N; Hong S; Yang Y; Ma Y; He D; Qin T; Zhou T; Tang Y; He X; Liang W; Zhang L
    Med Oncol; 2015 Mar; 32(3):61. PubMed ID: 25663066
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma.
    Calles A; Sholl LM; Rodig SJ; Pelton AK; Hornick JL; Butaney M; Lydon C; Dahlberg SE; Oxnard GR; Jackman DM; Jänne PA
    Clin Cancer Res; 2015 Jun; 21(12):2851-60. PubMed ID: 25737507
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Subtype-specific KRAS mutations in advanced lung adenocarcinoma: a retrospective study of patients treated with platinum-based chemotherapy.
    Cserepes M; Ostoros G; Lohinai Z; Raso E; Barbai T; Timar J; Rozsas A; Moldvay J; Kovalszky I; Fabian K; Gyulai M; Ghanim B; Laszlo V; Klikovits T; Hoda MA; Grusch M; Berger W; Klepetko W; Hegedus B; Dome B
    Eur J Cancer; 2014 Jul; 50(10):1819-1828. PubMed ID: 24768329
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of first-line immune checkpoint inhibitor and anti-angiogenic agent combination therapy for Kirsten rat sarcoma viral antigen-mutant advanced non-small-cell lung cancer: a systematic review and network meta-analysis.
    Tsukada A; Morita C; Shimizu Y; Uemura Y; Naka G; Takasaki J; Nokihara H; Izumi S; Hojo M
    Thorac Cancer; 2024 Sep; 15(25):1854-1862. PubMed ID: 39086088
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas.
    Yu HA; Sima CS; Shen R; Kass S; Gainor J; Shaw A; Hames M; Iams W; Aston J; Lovly CM; Horn L; Lydon C; Oxnard GR; Kris MG; Ladanyi M; Riely GJ
    J Thorac Oncol; 2015 Mar; 10(3):431-7. PubMed ID: 25415430
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.